BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 14, 2011
View Archived Issues
Pfizer synthesizes novel MAP kinase-activated protein kinase 2 inhibitors
Read More
Small-molecule DMART ameliorates SLE-like symptoms in vivo
Read More
Portola's recombinant factor Xa inhibitor antidote reverses rivaroxaban effects in vivo
Read More
New PLK1-inhibiting pyrimidodiazepinone derivatives identified
Read More
ApoA-I production enhancer reduces inflammatory biomarkers in CAD and may affect HDL functionality
Read More
Jasco Pharmaceuticals discloses novel casein kinase inhibitors
Read More
Phase II HQK-1001 trial in sickle cell disease fully enrolled
Read More
New voltage-gated sodium channel blockers synthesized at Amgen
Read More
Medivation presents novel neurotransmitter modulators
Read More
Juvaris and Colby Pharmaceutical enter agreement for CLDC technology and JVRS-100
Read More
Arch Biopartners selects lead agent for development in NSCLC and pancreatic cancer
Read More
New agents for viral infections patented by U.S. researchers
Read More
Ampla Pharmaceuticals describes novel IL-1 beta inhibitors
Read More
Pharmasset initiates screening for QUANTUM trial
Read More
OPA-6566 enters clinical development
Read More
Acceleron Pharma begins first-in-human study of ACE-536
Read More
Hawthorn Pharmaceuticals and CoPlex Therapeutics enter licensing deal
Read More
Ono Pharmaceutical set to launch Corebeta in Japan
Read More
Antisense Therapeutics begins multiple-dose stage of phase I ATL-1103 trial
Read More
Seattle Genetics and Oxford BioTherapeutics form antibody-drug conjugate collaboration
Read More
Abbott begins phase II study in uterine fibroids
Read More
Amicus and GSK initiate second phase III registration study of Amigal
Read More
Lexicon's antidiabetes candidate LX-4211 affects multiple parameters of glycemic control
Read More
Ono Pharmaceutical enters agreement with Servier for ivabradine
Read More
MorphoSys achieves second clinical milestone in anticancer antibody program with Bayer
Read More